Moderna stock plunges 25% after melanoma vaccine data leak
Moderna (MRNA) stock fell 25.2% to $183.88 on 22 October 2026 after leaked Phase 3 trial data for its melanoma vaccine showed a 42% risk reduction, below investor expectations of 49%. The selloff erased $24bn in market value. Merck (MRK), Moderna's partner, dropped 1%. Analysts attributed the reaction to high expectations and a sell-the-news move.
How this was made
The 30-second read
Why it matters
The leak caused a rapid price decline, but short‑interest levels were already high, suggesting limited further downside.
Market read
The article reports a material, first‑time disclosure of a data leak that drove a 25% stock plunge, making it highly relevant for traders.
What to watch
Potential positive reaction to upcoming full data presentation in Madrid could reverse the sell‑off.
Background
Moderna's melanoma vaccine had previously been benchmarked at a 49% risk reduction; the leaked Phase 3 readout showed a 42% reduction, prompting the sell‑off.
Ticker impact
Moderna shares fell 25% after a leak of Phase 3 melanoma vaccine data surfaced hours before a scheduled presentation.
likely continued pressure as investors reassess oncology revenue expectations.
The unexpected data leak undermined previously priced‑in expectations, and short interest was already elevated.
Market effects
Oncology biotech sector may see broader risk reassessment, but impact is limited to Moderna.
U.S. biotech indices likely dip; European markets less affected.
Limited to investors with exposure to Moderna and related oncology pipelines.
Counterpoint
Some traders may view the dip as an overreaction and consider a short‑term buying opportunity if the data holds up.
Key entities
- companyModerna, Inc.
Biotech firm developing mRNA‑based melanoma vaccine.
